Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Japanese biopharmaceutical start-up seeks about USD 10 million B-round financing
|Industry||Pharmeceuticals & Chemical|
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Senior Associate, International Business Advisory
|Project highlights||DNA & RNA editing - technology licencing|
The Japanese company develops DNA and RNA editing technology in the field of innovative medicines and chemical medicines, whose intellectual property assets may be granted rights to others under a licence, sublicence or other contract. The company's core is RNA-PPR technology. Its current products include repetitive motif RNA control platform, RNA splicing control platform and protein translation activation platform. The company seeks about USD 10 million (JPY 13 billion) B-round financing.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us